HOME >> MEDICINE >> NEWS
Foot-and-mouth 'on the move in Asia'

Australian foot-and-mouth expert Dr Laurie Gleeson has warned that the highly adaptable pan-Asian strain of Foot and Mouth Disease (FMD), responsible for the UK outbreaks, is on the move in South-East Asia.

Dr Gleeson has returned to CSIRO Livestock Industries Australian Animal Health Laboratory (AAHL) after spending four years in Thailand working as regional coordinator of the South East Asia FMD control program, run by the Office International des Epizooties (OIE) - the world organisation for animal health.

FMD appeared this year in the highlands of northern Laos, which is highly unusual. The pan-Asian strain seems to be very well adapted to pigs and cattle, and it has a capability to get around. This particular strain is now in every country of South East Asia that has FMD, says Dr Gleeson.

The outbreak of FMD in the UK and the spread of a new strain of FMD throughout South East Asia in recent times has put us on high alert.

The news comes as the Australian Animal Health Laboratory gears up its preparedness to deal with a potential outbreak of the dreaded livestock disease. AAHL is in the process of obtaining extra FMD test reagents, automating equipment, and training extra staff at the laboratory and at State diagnostic laboratories.

We realise that if the worst happens and there is an outbreak of FMD in Australia, we must be prepared to deal with a high volume of samples. We will need to be able to test samples from the outbreak area, and also from areas free from the disease, so they can resume trading as quickly as possible.

Our capability to quickly and accurately diagnose the first case of FMD has been high, but we recognised in the wake of the UK outbreak that we could do more to prepare for a long running outbreak of the disease, he says.

The training program and reagent purchase were made possible by the injection to AAHL of an additional $500,000 from the Federal Government.

Dr Gleeson sa
'"/>

Contact: Dr. Laurie Gleeson
Laurie.Gleeson@csiro.au
61-3-5227-5123
CSIRO Australia
7-Jan-2002


Page: 1 2 3

Related medicine news :

1. Gender bias leaves South Asias women in poor health

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Foot and mouth the move Asia

(Date:5/22/2013)... CoCENTRIX, a leading provider of coordinated ... Services and community providers, announced today that the ... CoCENTRIX Coordinated Care Platform (CoCENTRIXccp) as ... and coordinate care within and amongst its four ... transitioning the hospitals' official records from paper-based to ...
(Date:5/22/2013)... Denver, CO (PRWEB) May 22, 2013 ... of legal discovery management services for law firms, corporations ... Cumulus Data, Inc., a cloud-based e-discovery software company, to ... of this newly formed partnership, Cumulus Data and LDM ... Standard, downtown LA on Tuesday, May 21st. This ...
(Date:5/22/2013)... 2013 BroadConnect Telecom, the leading ... security solutions in North America announced plans to ... newest BroadConnect hosted security solutions. Available on premise, ... BroadConnect’s new Security as a Service (SaaS) enables ... connection of their choice, while optimizing internal network ...
(Date:5/22/2013)... Poor adherence to appropriate medication therapy has ... and death (some 125,000 deaths in the U.S. every ... costs. It’s been estimated that between 33% and 69% ... medication adherence — a reality that costs the American ... dire is the degree of medication non-adherence — and ...
(Date:5/22/2013)... Dallas, TX (PRWEB) May 22, 2013 Mari’s ... in Dallas, has become the first in the state of ... is called Meta Therapy- Medical and Esthetic Tissue Activation, also ... used for over four years in Europe, but has just ... Meta Therapy improves the skin from inside out by building ...
Breaking Medicine News(10 mins):Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 2Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 3Health News:BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business 2Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2Health News:Mari's to Offer New Treatment from Europe 2
(Date:5/22/2013)... , May 22, 2013  Grifols, a global ... , presented results from a study demonstrating that a ... Inhibitor [Human]) increased levels of the alpha 1 ... to levels that are considered within the normal range ... condition in which low levels of the alpha 1 ...
(Date:5/22/2013)... , May 22, 2013  BD (Becton, Dickinson ... global medical technology company, announced today the publication of ... fifth Sustainability Report and it continues to focus on ... "We believe the principles of shared value — ... healthcare challenges of societies — are fundamental to our ...
(Date:5/22/2013)... , May 22, 2013 Rigel Pharmaceuticals, Inc. ... advancement of three programs in development. The first program ... inhibitor, R348, being developed by Rigel as a treatment ... aimed at oncology targets and are being conducted by ... by BerGenBio AS (BerGenBio) and a ligase inhibitor under ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
Cached News: